

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTANSC1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 3 OCT 07 EPFULL enhanced with full implementation of EPC2000
NEWS 4 OCT 07 Multiple databases enhanced for more flexible patent
number searching
NEWS 5 OCT 22 Current-awareness alert (SDI) setup and editing
enhanced
NEWS 6 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
Applications
NEWS 7 OCT 24 CHEMLIST enhanced with intermediate list of
pre-registered REACH substances
NEWS 8 NOV 21 CAS patent coverage to include exemplified prophetic
substances identified in English-, French-, German-,
and Japanese-language basic patents from 2004-present
NEWS 9 NOV 26 MARPAT enhanced with FSORT command
NEWS 10 NOV 26 MEDLINE year-end processing temporarily halts
availability of new fully-indexed citations
NEWS 11 NOV 26 CHEMSAFE now available on STN Easy
NEWS 12 NOV 26 Two new SET commands increase convenience of STN
searching
NEWS 13 DEC 01 ChemPort single article sales feature unavailable
NEWS 14 DEC 12 GBFULL now offers single source for full-text
coverage of complete UK patent families
NEWS 15 DEC 17 Fifty-one pharmaceutical ingredients added to PS

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:02:37 ON 30 DEC 2008

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:03:12 ON 30 DEC 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 DEC 2008 HIGHEST RN 1091682-77-7

DICTIONARY FILE UPDATES: 29 DEC 2008 HIGHEST RN 1091682-77-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10574211A.str



chain nodes :

10 11 13

ring nodes :

1 2 3 4 5 6 7 8 9

ring/chain nodes :

12

chain bonds :

7-12 7-13 8-10 9-11

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
 exact/norm bonds :
 5-7 6-9 7-8 7-12 7-13 8-9 8-10 9-11
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
 11:CLASS 12:CLASS 13:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s sss sam l1

SAMPLE SEARCH INITIATED 10:03:35 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 165 TO ITERATE

100.0% PROCESSED 165 ITERATIONS

21 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 2530 TO 4070

PROJECTED ANSWERS: 146 TO 694

L2 21 SEA SSS SAM L1

=> d scan


L2 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 2-Pyrrolidinecarboxamide, 1-[3-(7-benzofuranyl)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)-


MF C31 H30 Cl N3 O8 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L2 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Indole-5-carbonitrile, 3-(6-chloro-2-ethoxy-3-pyridinyl)-2,3-dihydro-1-
[(5-methoxy-2-pyridinyl)sulfonyl]-2-oxo-3-[4-(1-piperazinyl)-1-
piperidinyl]-, hydrochloride (1:?)
MF C31 H34 Cl N7 O5 S . x Cl H




L2 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 2H-Indol-2-one, 5-chloro-1,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-3-(2-methoxy-3-pyridinyl)-3-[4-(2-thiazolyl)-1-piperazinyl]-
 MF C28 H26 Cl N5 O5 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-
 1H-indol-3-yl]-, (+)-
 MF C33 H36 N6 O5 S


Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-
 1H-indol-3-yl]-1'-(1-methylethyl)-, (+)-
 MF C36 H42 N6 O5 S

Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-
 [(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-piperazinyl)-
 MF C33 H37 N7 O6 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L2 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]-

MF C36 H43 N7 O6 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)-


MF C36 H43 N7 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-
 [(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-
 piperidinyl)-, (-)-
 MF C34 H39 N7 O6 S

Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1-Piperazinecarboxylic acid, 4-[1-[[[5-cyano-1-[(2,4-
 dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-
 indol-3-yl]amino]carbonyl]-4-piperidinyl]-, 1,1-dimethylethyl ester
 MF C39 H47 N7 O9 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxy-5-methyl-3-pyridinyl)-1-[[4-methoxy-2-(2,2,2-trifluoroethoxy)phenyl]sulfonyl]-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)-
 MF C31 H32 Cl F3 N4 O8 S

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0


```
=> s sss full l1
FULL SEARCH INITIATED 10:05:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      3312 TO ITERATE
```

```
100.0% PROCESSED      3312 ITERATIONS                      412 ANSWERS
SEARCH TIME: 00.00.01
```

```
L3      412 SEA SSS FUL L1
```

```
=> save temp l3 wilf10574211/a
ANSWER SET L3 HAS BEEN SAVED AS 'WILF10574211/A'
```

```
=>
Uploading C:\Program Files\STNEXP\Queries\10574211B.str
```



```
chain nodes :
10 11 13
ring nodes :
1 2 3 4 5 6 7 8 9
ring/chain nodes :
12
chain bonds :
7-12 7-13 8-10 9-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
5-7 6-9 7-8 7-12 7-13 8-9 8-10 9-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
```

```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:Atom
Generic attributes :
13:
Saturation      : Unsaturated
Type of Ring System : Monocyclic
```

L4 STRUCTURE UPLOADED

=> S L4 SUBSET=L3 SAM

SAMPLE SUBSET SEARCH INITIATED 10:10:29 FILE 'REGISTRY'

SAMPLE SUBSET SCREEN SEARCH COMPLETED - 21 TO ITERATE

100.0% PROCESSED 21 ITERATIONS

19 ANSWERS

SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):

ONLINE **COMPLETE**

PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):

146 TO 694

PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):

119 TO 641


L5 19 SEA SUB=L3 SSS SAM L4

=> D SCAN

L5 19 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1H-Indole-5-carbonitrile, 3-(6-chloro-2-ethoxy-3-pyridinyl)-2,3-dihydro-1-
[(5-methoxy-2-pyridinyl)sulfonyl]-2-oxo-3-[4-(1-piperazinyl)-1-
piperidinyl]-, hydrochloride (1:?)

MF C31 H34 Cl N7 O5 S . x Cl H



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> S L4 SUBSET=L3 FULL

FULL SUBSET SEARCH INITIATED 10:11:12 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 412 TO ITERATE

100.0% PROCESSED 412 ITERATIONS

362 ANSWERS

SEARCH TIME: 00.00.01

L6 362 SEA SUB=L3 SSS FUL L4

=> FIL CAPLUS

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

226.44

226.65

FILE 'CAPLUS' ENTERED AT 10:11:20 ON 30 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Dec 2008 VOL 150 ISS 1
FILE LAST UPDATED: 29 Dec 2008 (20081229/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> S L6

L7 8 L6

=> D IBIB ABS HITSTR 1-8

L7 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:1102517 CAPLUS Full-text
DOCUMENT NUMBER: 149:355701
TITLE: Preparation of substituted oxindole derivatives useful for the treatment of vasopressin-dependent and/or oxytocin-dependent diseases
INVENTOR(S): Geneste, Herve; Oost, Thorsten; Hutchins, Charles W.; Wernet, Wolfgang; Unger, Liliane; Hornberger, Wilfried; Lubisch, Wilfried; Netz, Astrid
PATENT ASSIGNEE(S): Abbott GmbH & Co. KG, Germany
SOURCE: PCT Int. Appl., 101pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2008107399	A1	20080912	WO 2008-EP52516	20080229
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:


US 2007-904627P

P 20070302

OTHER SOURCE(S):

MARPAT 149:355701

GI



AB Title compds. I [A = Ph or (un)substituted 5- to 6-membered heteroarom. ring; B = Ph, naphthyl or (un)substituted 5- to 10-membered mono- or bicyclic heteroarom. ring; R1 and R2 independently = H, halon, CN, NO₂, alkyl, haloalkyl, alkoxy or haloalkoxy; Y = cyclic bivalent group; Het = (un)substituted 5- to 6-membered (un)saturated or aromatic heterocyclyl], and their tautomeric, enantiomeric and/or diastereomeric forms thereof, and the prodrugs and the physiol. tolerated salts and N-oxides of said compds., are prepared useful for the prophylaxis and/or treatment of vasopressin-dependent and/or oxytocin-dependent diseases. Thus, e.g., II was prepared by condensation reaction of 1-(pyridin-4-yl)piperazine with 5-chloro-3-(2,4-dimethoxyphenyl)-3-hydroxy-1,3-dihydroindol-2-one followed by sulfonylation with 8-quinolinesulfonyl chloride. The invention compds. were evaluated for their affinity for the V1b receptor in human vasopressin V1b receptor binding assay, e.g., II demonstrated a K_i value of < 10 nM for the V1b receptor.

IT 1056550-98-1P, 5-Cyano-3-(2,6-difluoropyridin-3-yl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-[4-(pyridin-4-yl)piperazin-1-yl]-2,3-dihydro-1H-indol-2-one 1056551-34-8P, 5-Chloro-1-[(4-methoxyphenyl)sulfonyl]-3-(2-methoxypyridin-3-yl)-3-[4-(thiazol-2-yl)piperazin-1-yl]-1,3-dihydroindol-2-one 1056551-35-9P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxypyridin-3-yl)-3-[4-(thiazol-2-yl)piperazin-1-yl]-1,3-dihydroindol-2-one 1056551-36-0P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxypyridin-3-yl)-3-[4-(pyridin-4-yl)piperazin-1-yl]-1,3-dihydroindol-2-one 1056551-37-1P, 5-Chloro-1-[(4-methoxyphenyl)sulfonyl]-3-(2-methoxypyridin-3-yl)-3-[4-(pyridin-4-yl)piperazin-1-yl]-1,3-dihydroindol-2-one 1056551-38-2P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxypyridin-3-yl)-3-[4-(4-cyanopyridin-2-yl)piperazin-1-yl]-1,3-dihydroindol-2-one 1056551-39-3P, 5-Chloro-1-[(2-methoxy-4-methylphenyl)sulfonyl]-3-(2-methoxypyridin-3-yl)-3-[4-(pyridin-4-yl)piperazin-1-yl]-1,3-dihydroindol-2-one 1056551-40-6P, 5-Chloro-1-[(4-cyanophenyl)sulfonyl]-3-(2-methoxypyridin-3-yl)-3-[4-(pyridin-4-yl)piperazin-1-yl]-1,3-dihydroindol-2-


one 1056551-41-7P, 5-Chloro-1-[(2-methoxyphenyl)sulfonyl]-3-(2-methoxypyridin-3-yl)-3-[4-(pyridin-4-yl)piperazin-1-yl]-1,3-dihydroindol-2-one 1056551-42-8P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-[4-(4-methoxyphenyl)piperazin-1-yl]-3-(2-methoxypyridin-3-yl)-1,3-dihydroindol-2-one 1056551-43-9P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxypyridin-3-yl)-3-[4-(pyridin-2-yl)piperazin-1-yl]-1,3-dihydroindol-2-one 1056551-44-0P, 5-Chloro-1-[(2-fluorophenyl)sulfonyl]-3-(2-methoxypyridin-3-yl)-3-[4-(pyridin-4-yl)piperazin-1-yl]-1,3-dihydroindol-2-one 1056551-45-1P, 5-Chloro-1-[(4-fluorophenyl)sulfonyl]-3-(2-methoxypyridin-3-yl)-3-[4-(pyridin-4-yl)piperazin-1-yl]-1,3-dihydroindol-2-one 1056551-46-2P, 5-Chloro-1-[(3,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxypyridin-3-yl)-3-[4-(pyridin-2-yl)piperazin-1-yl]-1,3-dihydroindol-2-one 1056551-71-3P, 5-Cyano-3-(6-chloro-2-methoxypyridin-3-yl)-3-[4-(pyridin-4-yl)piperazin-1-yl]-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-1H-indol-2-one 1056551-76-8P, 5-Cyano-3-(2,6-dimethoxypyridin-3-yl)-3-[4-(pyridin-4-yl)piperazin-1-yl]-1-[(quinolin-8-yl)sulfonyl]-1,3-dihydroindol-2-one 1056551-77-9P, 5-Cyano-3-(2,6-dimethoxypyridin-3-yl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-[4-(pyridin-4-yl)piperazin-1-yl]-2,3-dihydro-1H-indol-2-one 1056551-78-0P, 5-Cyano-3-(6-chloro-2-ethoxypyridin-4-yl)-1-[(5-methylpyridin-2-yl)sulfonyl]-3-[4-(pyridin-4-yl)piperazin-1-yl]-2,3-dihydro-1H-indol-2-one 1056551-79-1P, 5-Cyano-3-(6-chloro-2-ethoxypyridin-4-yl)-3-[4-(pyridin-4-yl)piperazin-1-yl]-1-[(quinolin-8-yl)sulfonyl]-1,3-dihydroindol-2-one

RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted oxindole derivs. for the treatment and prophylaxis of vasopressin-dependent and/or oxytocin-dependent diseases)


RN 1056550-98-1 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-(2,6-difluoro-3-pyridinyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1056551-34-8 CAPLUS

CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-3-(2-methoxy-3-pyridinyl)-3-[4-(2-thiazolyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1056551-35-9 CAPLUS

CN 2H-Indol-2-one, 5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-(2-methoxy-3-pyridinyl)-3-[4-(2-thiazolyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1056551-36-0 CAPLUS

CN 2H-Indol-2-one, 5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-(2-methoxy-3-pyridinyl)-3-[4-(4-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1056551-37-1 CAPLUS

CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-3-(2-methoxy-3-pyridinyl)-3-[4-(4-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1056551-38-2 CAPLUS

CN 4-Pyridinecarbonitrile, 2-[4-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxy-3-pyridinyl)-2-oxo-1H-indol-3-yl]-1-piperazinyl]- (CA INDEX NAME)




RN 1056551-39-3 CAPLUS

CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-1-[(2-methoxy-4-methylphenyl)sulfonyl]-3-(2-methoxy-3-pyridinyl)-3-[4-(4-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1056551-40-6 CAPLUS

CN Benzonitrile, 4-[[5-chloro-2,3-dihydro-3-(2-methoxy-3-pyridinyl)-2-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]-1H-indol-1-yl]sulfonyl]- (CA INDEX NAME)




RN 1056551-41-7 CAPLUS

CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-3-(2-methoxy-3-pyridinyl)-3-[4-(4-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1056551-42-8 CAPLUS

CN 2H-Indol-2-one, 5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-[4-(4-methoxyphenyl)-1-piperazinyl]-3-(2-methoxy-3-pyridinyl)- (CA INDEX NAME)




RN 1056551-43-9 CAPLUS

CN 2H-Indol-2-one, 5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-(2-methoxy-3-pyridinyl)-3-[4-(2-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1056551-44-0 CAPLUS

CN 2H-Indol-2-one, 5-chloro-1-[(2-fluorophenyl)sulfonyl]-1,3-dihydro-3-(2-methoxy-3-pyridinyl)-3-[4-(4-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1056551-45-1 CAPLUS

CN 2H-Indol-2-one, 5-chloro-1-[(4-fluorophenyl)sulfonyl]-1,3-dihydro-3-(2-methoxy-3-pyridinyl)-3-[4-(4-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1056551-46-2 CAPLUS

CN 2H-Indol-2-one, 5-chloro-1-[(3,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-(2-methoxy-3-pyridinyl)-3-[4-(2-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1056551-71-3 CAPLUS


CN 1H-Indole-5-carbonitrile, 3-(6-chloro-2-methoxy-3-pyridinyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1056551-76-8 CAPLUS
 CN 1H-Indole-5-carbonitrile, 3-(2,6-dimethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]-1-(8-quinolinylsulfonyl)- (CA INDEX NAME)



RN 1056551-77-9 CAPLUS
 CN 1H-Indole-5-carbonitrile, 1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2,6-dimethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1056551-78-0 CAPLUS
 CN 1H-Indole-5-carbonitrile, 3-(2-chloro-6-ethoxy-4-pyridinyl)-2,3-dihydro-1-[(5-methyl-2-pyridinyl)sulfonyl]-2-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)



RN 1056551-79-1 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-(2-chloro-6-ethoxy-4-pyridinyl)-2,3-dihydro-2-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]-1-(8-quinolinylsulfonyl)- (CA INDEX NAME)



IT 1056550-46-9P, 5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-3-[4-(pyridin-4-yl)piperazin-1-yl]-2,3-dihydro-1H-indol-2-one 1056550-47-0P, 5-Cyano-3-(2-methoxypyridin-3-yl)-3-[4-(pyridin-4-yl)piperazin-1-yl]-1-[(quinolin-8-yl)sulfonyl]-2,3-dihydro-1H-indol-2-one 1056550-48-1P, 5-Cyano-3-(2-ethoxypyridin-3-yl)-3-[4-(pyridin-4-yl)piperazin-1-yl]-1-[(quinolin-8-yl)sulfonyl]-2,3-dihydro-1H-indol-2-one 1056550-51-6P, 5-Chloro-3-(pyridin-2-yl)-3-[4-(pyridin-4-yl)piperazin-1-yl]-1-[(quinolin-8-yl)sulfonyl]-1,3-dihydroindol-2-one 1056550-52-7P, 5-Chloro-3-(3-methylpyridin-2-yl)-3-[4-(pyridin-4-yl)piperazin-1-yl]-1-[(quinolin-8-yl)sulfonyl]-1,3-dihydroindol-2-one 1056550-53-8P, 5-Chloro-3-(6-chloro-2-methoxypyridin-3-yl)-3-[4-(pyridin-4-yl)piperazin-1-yl]-1-[(quinolin-8-yl)sulfonyl]-1,3-dihydroindol-2-one 1056550-62-9P, (-)-5-Cyano-3-(6-chloro-2-methoxypyridin-3-yl)-3-[4-(pyridin-4-yl)piperazin-1-yl]-1-[(quinolin-8-yl)sulfonyl]-2,3-dihydro-1H-indol-2-one 1056550-66-3P, (-)-5-Cyano-3-(6-chloro-2-ethoxypyridin-3-yl)-1-[(5-methylpyridin-2-yl)sulfonyl]-3-[4-(pyridin-4-yl)piperazin-1-yl]-2,3-dihydro-1H-indol-2-one 1056550-67-4P, (-)-5-Cyano-3-(6-chloro-2-ethoxypyridin-3-yl)-3-[4-(pyridin-4-yl)piperazin-1-yl]-1-[(quinolin-8-yl)sulfonyl]-2,3-dihydro-1H-


indol-2-one 1056550-70-9P,
5-Cyano-3-(6-chloro-2-ethoxypyridin-3-yl)-3-[4-(2-methylpyridin-4-yl)piperazin-1-yl]-1-[(quinolin-8-yl)sulfonyl]-2,3-dihydro-1H-indol-2-one 1056550-71-0P, 5-Cyano-3-(6-chloro-2-ethoxypyridin-3-yl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-[4-(2-methylpyridin-4-yl)piperazin-1-yl]-2,3-dihydro-1H-indol-2-one 1056550-72-1P,
5-Cyano-3-(6-chloro-2-ethoxypyridin-3-yl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-[4-(pyridin-4-yl)piperazin-1-yl]-2,3-dihydro-1H-indol-2-one 1056550-73-2P,
5-Cyano-3-(6-chloro-2-ethoxypyridin-3-yl)-1-[(4-methylquinolin-8-yl)sulfonyl]-3-[4-(pyridin-4-yl)piperazin-1-yl]-2,3-dihydro-1H-indol-2-one 1056550-77-6P, 5-Cyano-3-(6-chloro-2-ethoxypyridin-3-yl)-1-[(5-methoxypyridin-2-yl)sulfonyl]-3-[4-(2-methylpyridin-4-yl)piperazin-1-yl]-2,3-dihydro-1H-indol-2-one 1056550-79-8P,
5-Cyano-3-(6-chloro-2-ethoxypyridin-3-yl)-1-[(5-methoxypyridin-2-yl)sulfonyl]-3-[4-(pyridin-4-yl)piperazin-1-yl]-2,3-dihydro-1H-indol-2-one 1056550-85-6P, 5-Chloro-3-(2-methoxypyridin-3-yl)-3-[4-(pyridin-4-yl)piperazin-1-yl]-1-[(quinolin-8-yl)sulfonyl]-1,3-dihydroindol-2-one 1056551-13-3P, 5-Cyano-3-(6-chloro-2-ethoxypyridin-3-yl)-1-[(5-methoxyquinolin-8-yl)sulfonyl]-3-[4-(pyridin-4-yl)-[1,4]diazepan-1-yl]-2,3-dihydro-1H-indol-2-one 1056551-27-9P,
5-Cyano-3-(6-chloro-2-ethoxypyridin-3-yl)-1-[(5-methoxyquinolin-8-yl)sulfonyl]-3-[4-(2-methylpyridin-4-yl)piperazin-1-yl]-2,3-dihydro-1H-indol-2-one 1056551-92-8P,
5-Cyano-3-(6-chloro-2-ethoxypyridin-3-yl)-1-[(5-methoxypyridin-2-yl)sulfonyl]-3-[5-(pyridin-4-yl)hexahydropyrrolo[3,4-c]pyrrol-2-yl]-2,3-dihydro-1H-indol-2-one 1056551-93-9P,
5-Cyano-3-(6-chloro-2-ethoxypyridin-3-yl)-1-[(5-methoxypyridin-2-yl)sulfonyl]-3-[5-(2-methylpyridin-4-yl)hexahydropyrrolo[3,4-c]pyrrol-2-yl]-2,3-dihydro-1H-indol-2-one 1056551-95-1P
1056551-96-2P 1056551-99-5P 1056552-10-3P,
5-Cyano-3-(6-chloro-2-ethoxypyridin-3-yl)-3-[4-(2-isopropylpyridin-4-yl)piperazin-1-yl]-1-[(5-methoxypyridin-2-yl)sulfonyl]-2,3-dihydro-1H-indol-2-one 1056552-11-4P,
5-Cyano-3-(6-chloro-2-ethoxypyridin-3-yl)-1-[(5-methoxypyridin-2-yl)sulfonyl]-3-[4-(pyridin-4-yl)-[1,4]diazepan-1-yl]-2,3-dihydro-1H-indol-2-one 1056552-13-6P, 5-Cyano-3-(6-chloro-2-ethoxypyridin-3-yl)-1-[(5-methoxypyridin-2-yl)sulfonyl]-3-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2,3-dihydro-1H-indol-2-one 1056552-20-5P
1056552-22-7P 1056552-29-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted oxindole derivs. for the treatment and prophylaxis of vasopressin-dependent and/or oxytocin-dependent diseases)


RN 1056550-46-9 CAPLUS

CN 1H-Indole-5-carbonitrile, 1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1056550-47-0 CAPLUS

CN 1H-Indole-5-carbonitrile, 2,3-dihydro-3-(2-methoxy-3-pyridinyl)-2-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]-1-(8-quinolinylsulfonyl)- (CA INDEX NAME)




RN 1056550-48-1 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]-1-(8-quinolinylsulfonyl)- (CA INDEX NAME)




RN 1056550-51-6 CAPLUS

CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-(2-pyridinyl)-3-[4-(4-pyridinyl)-1-piperazinyl]-1-(8-quinolinylsulfonyl)- (CA INDEX NAME)




RN 1056550-52-7 CAPLUS

CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-(3-methyl-2-pyridinyl)-3-[4-(4-pyridinyl)-1-piperazinyl]-1-(8-quinolinylsulfonyl)- (CA INDEX NAME)




RN 1056550-53-8 CAPLUS

CN 2H-Indol-2-one, 5-chloro-3-(6-chloro-2-methoxy-3-pyridinyl)-1,3-dihydro-3-[4-(4-pyridinyl)-1-piperazinyl]-1-(8-quinolinylsulfonyl)- (CA INDEX NAME)




RN 1056550-62-9 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-(6-chloro-2-methoxy-3-pyridinyl)-2,3-dihydro-2-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]-1-(8-quinolinylsulfonyl)- (CA INDEX NAME)




RN 1056550-66-3 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-(6-chloro-2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(5-methyl-2-pyridinyl)sulfonyl]-2-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1056550-67-4 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-(6-chloro-2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]-1-(8-quinolinylsulfonyl)- (CA INDEX NAME)




RN 1056550-70-9 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-(6-chloro-2-ethoxy-3-pyridinyl)-2,3-dihydro-3-[4-(2-methyl-4-pyridinyl)-1-piperazinyl]-2-oxo-1-(8-quinolinylsulfonyl)- (CA INDEX NAME)




RN 1056550-71-0 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-(6-chloro-2-ethoxy-3-pyridinyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-[4-(2-methyl-4-pyridinyl)-1-piperazinyl]-2-oxo- (CA INDEX NAME)




RN 1056550-72-1 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-(6-chloro-2-ethoxy-3-pyridinyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1056550-73-2 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-(6-chloro-2-ethoxy-3-pyridinyl)-2,3-dihydro-1-
 [(4-methyl-8-quinolinyl)sulfonyl]-2-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]-
 (CA INDEX NAME)




RN 1056550-77-6 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-(6-chloro-2-ethoxy-3-pyridinyl)-2,3-dihydro-1-
 [(5-methoxy-2-pyridinyl)sulfonyl]-3-[4-(2-methyl-4-pyridinyl)-1-
 piperazinyl]-2-oxo- (CA INDEX NAME)




RN 1056550-79-8 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-(6-chloro-2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(5-methoxy-2-pyridinyl)sulfonyl]-2-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1056550-85-6 CAPLUS


CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-(2-methoxy-3-pyridinyl)-3-[4-(4-pyridinyl)-1-piperazinyl]-1-(8-quinolinylsulfonyl)- (CA INDEX NAME)




RN 1056551-13-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056551-27-9 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-(6-chloro-2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(5-methoxy-8-quinolinyl)sulfonyl]-3-[4-(2-methyl-4-pyridinyl)-1-piperazinyl]-2-oxo- (CA INDEX NAME)



RN 1056551-92-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056551-93-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1056551-95-1 CAPLUS
 CN 1H-Indole-5-carbonitrile, 3-(6-chloro-2-ethoxy-3-pyridinyl)-2,3-dihydro-1-
 [(5-methoxy-2-pyridinyl)sulfonyl]-3-[4-(2-methyl-4-pyridinyl)-1-
 piperazinyl]-2-oxo-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1056551-96-2 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1056551-95-1
 CMF C32 H30 Cl N7 O5 S

Rotation (+).




CM 2

CRN 75-75-2
 CMF C H4 O3 S




RN 1056551-99-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



Absolute stereochemistry.



RN 1056552-10-3 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-(6-chloro-2-ethoxy-3-pyridinyl)-2,3-dihydro-1-
[(5-methoxy-2-pyridinyl)sulfonyl]-3-[4-[2-(1-methylethyl)-4-pyridinyl]-1-
piperazinyl]-2-oxo- (CA INDEX NAME)




RN 1056552-11-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056552-13-6 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-(6-chloro-2-ethoxy-3-pyridinyl)-2,3-dihydro-1-
[(5-methoxy-2-pyridinyl)sulfonyl]-3-[4-(4-methyl-1-piperazinyl)-1-
piperidinyl]-2-oxo- (CA INDEX NAME)



RN 1056552-20-5 CAPLUS


CN INDEX NAME NOT YET ASSIGNED



RN 1056552-22-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


CM 1

CRN 1056552-21-6
CMF C33 H32 Cl N7 O5 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 1056552-29-4 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-(6-chloro-2-ethoxy-3-pyridinyl)-2,3-dihydro-1-
[(5-methoxy-2-pyridinyl)sulfonyl]-2-oxo-3-[4-(1-piperazinyl)-1-
piperidinyl]-, hydrochloride (1:?) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:824755 CAPLUS Full-text

DOCUMENT NUMBER: 149:153121

TITLE: Preparation of substituted oxindole derivative as
vasopressin receptor modulators

INVENTOR(S): Netz, Astrid; Oost, Thorsten; Geneste, Herve; Braje,
Wilfried Martin; Wernet, Wolfgang; Unger, Liliane;
Hornberger, Wilfried; Lubisch, Wilfried

PATENT ASSIGNEE(S): Abbott G.m.b.H. & Co. K.-G., Germany

SOURCE: PCT Int. Appl., 37pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008080971	A1	20080710	WO 2007-EP64620	20071228
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.:

DE 2006-102006062507A 20061230

GI




AB The present invention relates to novel oxindole derivs. of the formula I to medicaments comprising them and to their use for the prophylaxis and/or treatment of diseases vasopressin dependent. Thus, I was provided in a multi-step synthesis starting from the reaction of 5-iodoisatin with 2-ethoxy-3-iodopyridine. I was tested in binding assay of Vasopressin receptor V1a, V1b and V2, and oxytocin receptor, the other biol. assays were described as well.

IT 1037238-28-0P, N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidine-1-carboxamide

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (preparation of substituted oxindole derivative as vasopressin receptor modulators)

RN 1037238-28-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



IT 1037238-64-4P 1037238-66-6P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of substituted oxindole derivative as vasopressin receptor modulators)

RN 1037238-64-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-

piperazinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1037238-66-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, (-)- (CA INDEX NAME)


Rotation (-).




IT 1037238-19-9P, 3-Amino-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxoindoline-5-carbonitrile 1037238-20-2P, Phenyl [5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]carbamate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted oxindole derivative as vasopressin receptor modulators)

RN 1037238-19-9 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-amino-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo- (CA INDEX NAME)



RN 1037238-20-2 CAPLUS
 CN Carbamic acid, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-, phenyl ester (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:824754 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 149:153120
 TITLE: Preparation of substituted oxindole derivative as vasopressin receptor modulators
 INVENTOR(S): Netz, Astrid; Oost, Thorsten; Geneste, Herve; Braje, Wilfried Martin; Wernet, Wolfgang; Unger, Liliane; Hornberger, Wilfried; Lubisch, Wilfried
 PATENT ASSIGNEE(S): Abbott G.m.b.H. & Co. K.-G., Germany
 SOURCE: PCT Int. Appl., 37pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008080970	A1	20080710	WO 2007-EP64619	20071228
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				

BY, KG, KZ, MD, RU, TJ, TM
 PRIORITY APPLN. INFO.:
 GI

DE 2006-102006062508A 20061230




AB The present invention relates to novel oxindole derivs. of the formula I to medicaments comprising them and to their use for the prophylaxis and/or treatment of diseases vasopressin dependent. Thus, I was provided in a multi-step synthesis starting from the reaction of 5-iodoisatin with 2-ethoxy-3-iodopyridine. I was tested in binding assay of Vasopressin receptor V1a, V1b and V2, and oxytocin receptor, the other biol. assays were described as well.

IT 1037238-14-4P, N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-carboxamide

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (preparation of substituted oxindole derivative as vasopressin receptor modulators)

RN 1037238-14-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



IT 1037238-60-0P 1037238-62-2P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN

(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); USES (Uses)
 (preparation of substituted oxindole derivative as vasopressin receptor
 modulators)

RN 1037238-60-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1037238-62-2 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, (-)- (CA INDEX NAME)

Rotation (-).




IT 1037238-19-9P, 3-Amino-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxoindoline-5-carbonitrile 1037238-20-2P,
 Phenyl [5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-
 2-oxo-2,3-dihydro-1H-indol-3-yl]carbamate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of substituted oxindole derivative as vasopressin receptor
 modulators)

RN 1037238-19-9 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-amino-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo- (CA INDEX NAME)



RN 1037238-20-2 CAPLUS
CN Carbamic acid, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-, phenyl ester (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:824753 CAPLUS [Full-text](#)
DOCUMENT NUMBER: 149:153119
TITLE: Preparation of substituted oxindole derivative as vasopressin receptor modulators
INVENTOR(S): Netz, Astrid; Oost, Thorsten; Geneste, Herve; Braje, Wilfried Martin; Wernet, Wolfgang; Unger, Liliane; Hornberger, Wilfried; Lubisch, Wilfried
PATENT ASSIGNEE(S): Abbott G.m.b.H. & Co. K.-G., Germany
SOURCE: PCT Int. Appl., 98pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008080973	A1	20080710	WO 2007-EP64622	20071228
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,			


TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

DE 2006-102006062505A 20061230
 DE 2006-102006062506A 20061230
 DE 2006-102006062507A 20061230
 DE 2006-102006062508A 20061230

OTHER SOURCE(S): MARPAT 149:153119

GI




AB Title compds. represented by the formula I [wherein R1 = EtO; R2 = R4 = H; R3 = CN; R5 = H, MeO or EtO; R6 = H or MeO; R7 = H, Me, Et, Pr or isopropyl; X1 = -NH-; X2 = N or CH; X3 = N or CH; where X2 and X3 are not simultaneously N; and pharmaceutically acceptable salts, tautomeric forms and prodrugs thereof] were prepared as vasopressin receptor modulators for the prophylaxis and/or treatment of diseases vasopressin dependent. Thus, I [R1 = EtO, R2 = R4 = H, R3 = CN, R5 = R6 = MeO, R7 = Me, X1 = -NH-; X2 = N, X3 = CH] was provided in a multi-step synthesis starting from the reaction of 5-iodoisatin with 2-ethoxy-3-iodopyridine. The invention compds. were tested in binding assay of Vasopressin receptor V1a, V1b and V2, and oxytocin receptor, the other biol. assays were described as well.

IT 1037238-14-4P 1037238-28-0P 1037238-36-0P

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (preparation of substituted oxindole derivative as vasopressin receptor modulators)


RN 1037238-14-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1037238-28-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 1037238-36-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)- (CA INDEX NAME)



IT 1037238-60-0P 1037238-62-2P 1037238-64-4P

1037238-66-6P 1037238-68-8P 1037238-70-2P

1037238-73-5P 1037238-75-7P 1037238-81-5P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN

(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses)
(preparation of substituted oxindole derivative as vasopressin receptor
modulators)

RN 1037238-60-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1037238-62-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1037238-64-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1037238-66-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1037238-68-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1037238-70-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1037238-73-5 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-ethyl-4-piperidinyl)-, (-)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1037238-72-4

CMF C36 H43 N7 O7 S


Rotation (-).



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 1037238-75-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1037238-81-5 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-1'-ethyl-, (-)-, 2,2,2-trifluoroacetate, hydrochloride (1:1:1) (CA INDEX NAME)

CM 1


CRN 1037238-80-4
CMF C37 H44 N6 O7 S

Rotation (-).




CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 1037238-55-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted oxindole derivative as vasopressin receptor modulators)
RN 1037238-55-3 CAPLUS
CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


IT 1037238-21-3P 1037238-24-6P 1037238-26-8P
 1037238-27-9P 1037238-29-1P 1037238-31-5P
 1037238-32-6P 1037238-34-8P 1037238-38-2P
 1037238-40-6P 1037238-42-8P 1037238-48-4P
 1037238-51-9P 1037238-53-1P 1037238-58-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of substituted oxindole derivative as vasopressin receptor
 modulators)


RN 1037238-21-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-
 [(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-
 piperidinyl)- (CA INDEX NAME)



RN 1037238-24-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-
 [(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-
 piperidinyl)- (CA INDEX NAME)




RN 1037238-26-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1037238-25-7


CMF C35 H41 N7 O6 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 1037238-27-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1037238-29-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 1037238-31-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1037238-30-4


CMF C35 H41 N7 O6 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 1037238-32-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 1037238-34-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1037238-33-7


CMF C34 H39 N7 O6 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 1037238-38-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)- (CA INDEX NAME)




RN 1037238-40-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)- (CA INDEX NAME)



RN 1037238-42-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-piperazinyl)- (CA INDEX NAME)




RN 1037238-48-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-piperidinyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 1037238-47-3


CMF C34 H39 N7 O7 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1037238-51-9 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 1037238-50-8


CMF C35 H40 N6 O7 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 1037238-53-1 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
dihydro-2-oxo-1H-indol-3-yl]-1'-methyl- (CA INDEX NAME)



RN 1037238-58-6 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-

dihydro-2-oxo-1H-indol-3-yl]-1'-ethyl-, 2,2,2-trifluoroacetate,
hydrochloride (1:1:1) (CA INDEX NAME)

CM 1

CRN 1037238-57-5


CMF C37 H44 N6 O7 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 1037238-19-9P 1037238-20-2P 1037238-44-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of substituted oxindole derivative as vasopressin receptor
modulators)


RN 1037238-19-9 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-amino-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-
ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo- (CA INDEX NAME)




RN 1037238-20-2 CAPLUS

CN Carbamic acid, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-, phenyl ester (CA INDEX NAME)



RN 1037238-44-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[[[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]amino]carbonyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 1042659-61-9P 1042659-62-0P 1042659-63-1P
 1042659-64-2P 1042659-65-3P 1042659-66-4P
 1042659-67-5P 1042659-68-6P 1042659-69-7P
 1042659-70-0P 1042659-71-1P 1042659-72-2P
 1042659-73-3P 1042659-74-4P 1042659-75-5P
 1042659-76-6P 1042659-77-7P 1042659-78-8P
 1042659-79-9P 1042659-80-2P 1042659-81-3P
 1042659-82-4P 1042659-83-5P 1042659-84-6P
 1042659-85-7P 1042659-86-8P 1042659-87-9P
 1042659-88-0P 1042659-89-1P 1042659-90-4P
 1042659-91-5P 1042659-92-6P 1042659-93-7P
 1042659-94-8P 1042659-95-9P 1042659-96-0P
 1042659-97-1P 1042659-99-3P 1042660-00-3P
 1042660-01-4P 1042660-02-5P 1042660-03-6P
 1042660-04-7P 1042660-05-8P 1042660-06-9P
 1042660-07-0P 1042660-08-1P 1042660-09-2P
 1042660-10-5P 1042660-11-6P 1042660-12-7P
 1042660-13-8P 1042660-14-9P 1042660-15-0P
 1042660-16-1P 1042660-17-2P 1042660-18-3P
 1042660-19-4P 1042660-20-7P 1042660-22-9P
 1042660-23-0P 1042660-24-1P 1042660-25-2P
 1042660-26-3P 1042660-27-4P 1042660-28-5P
 1042660-29-6P 1042660-30-9P 1042660-31-0P

1042660-32-1P 1042660-33-2P 1042660-34-3P
1042660-35-4P 1042660-36-5P 1042660-37-6P
1042660-38-7P 1042660-39-8P 1042660-40-1P
1042660-41-2P 1042660-42-3P 1042660-43-4P
1042660-44-5P 1042660-45-6P 1042660-46-7P
1042660-47-8P 1042660-48-9P 1042660-49-0P
1042660-50-3P 1042660-51-4P 1042660-52-5P
1042660-53-6P 1042660-54-7P 1042660-55-8P
1042660-56-9P 1042660-57-0P 1042660-58-1P
1042660-59-2P 1042660-60-5P 1042660-61-6P
1042660-62-7P 1042660-63-8P 1042660-64-9P
1042660-65-0P 1042660-66-1P 1042660-67-2P
1042660-68-3P 1042660-69-4P 1042660-70-7P
1042660-71-8P 1042660-72-9P 1042660-73-0P
1042660-74-1P 1042660-75-2P 1042660-76-3P
1042660-77-4P 1042660-78-5P 1042660-79-6P
1042660-80-9P 1042660-81-0P 1042660-82-1P
1042660-83-2P 1042660-84-3P 1042660-85-4P
1042660-86-5P 1042660-87-6P 1042660-88-7P
1042660-89-8P 1042660-90-1P 1042660-91-2P
1042660-92-3P 1042660-93-4P 1042660-94-5P
1042660-95-6P 1042660-96-7P 1042660-97-8P
1042660-98-9P 1042660-99-0P 1042661-00-6P
1042661-01-7P 1042661-02-8P 1042661-03-9P
1042661-04-0P 1042661-05-1P 1042661-06-2P
1042661-07-3P 1042661-08-4P 1042661-09-5P
1042661-10-8P 1042661-11-9P 1042661-12-0P
1042661-13-1P 1042661-14-2P 1042661-15-3P
1042661-16-4P 1042661-17-5P 1042661-18-6P
1042661-20-0P 1042661-21-1P 1042661-22-2P
1042661-23-3P 1042661-24-4P 1042661-25-5P
1042661-26-6P 1042661-27-7P 1042661-28-8P
1042661-29-9P 1042661-30-2P 1042661-31-3P
1042661-32-4P 1042661-33-5P 1042661-34-6P
1042661-35-7P 1042661-36-8P 1042661-37-9P
1042661-38-0P 1042661-39-1P 1042661-40-4P
1042661-41-5P 1042661-42-6P 1042661-43-7P
1042661-44-8P 1042661-45-9P 1042661-46-0P
1042661-47-1P 1042661-48-2P 1042661-49-3P
1042661-50-6P 1042661-51-7P 1042661-52-8P
1042661-53-9P 1042661-54-0P 1042661-55-1P
1042661-56-2P 1042661-57-3P 1042661-58-4P
1042661-59-5P 1042661-60-8P 1042661-61-9P
1042661-62-0P 1042661-63-1P 1042661-64-2P
1042661-65-3P 1042661-66-4P 1042661-67-5P
1042661-68-6P 1042661-69-7P 1042661-70-0P
1042661-71-1P 1042661-72-2P 1042661-73-3P
1042661-74-4P 1042661-75-5P 1042661-76-6P
1042661-77-7P 1042661-78-8P 1042661-79-9P
1042661-80-2P 1042661-81-3P 1042661-82-4P
1042661-83-5P 1042661-84-6P 1042661-85-7P
1042661-86-8P 1042661-87-9P 1042661-88-0P
1042661-90-4P 1042661-91-5P 1042661-92-6P
1042661-93-7P 1042661-94-8P 1042661-95-9P
1042661-96-0P 1042661-97-1P

RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prophetic drug candidate; novel substituted oxindole derivs. as vasopressin receptor ligands useful in prophylaxis and treatment of

vasopressin-dependent diseases)

RN 1042659-61-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042659-62-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1042659-63-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042659-64-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1042659-65-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, (+)-(CA INDEX NAME)


Rotation (+).



RN 1042659-66-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1042659-67-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042659-68-6 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042659-69-7 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1042659-70-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042659-71-1 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042659-72-2 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-ethyl-4-piperidinyl)- (CA INDEX NAME)



RN 1042659-73-3 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-ethyl-4-piperidinyl)-, (+)- (CA INDEX NAME)

Rotation (+).



RN 1042659-74-4 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-ethyl-4-piperidinyl)- (CA INDEX NAME)



RN 1042659-75-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-ethyl-4-piperidinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042659-76-6 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-
[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-ethyl-4-piperidinyl)-
, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042659-77-7 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-
ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-ethyl-4-
piperidinyl)- (CA INDEX NAME)



RN 1042659-78-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-
ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-ethyl-4-
piperidinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042659-79-9 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-ethyl-4-piperidinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042659-80-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(1-ethyl-4-piperidinyl)- (CA INDEX NAME)




RN 1042659-81-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-

oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(1-ethyl-4-piperidinyl)-, (+)-
(CA INDEX NAME)


Rotation (+).



RN 1042659-82-4 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(1-ethyl-4-piperidinyl)-, (-)-
(CA INDEX NAME)

Rotation (-).



RN 1042659-83-5 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-ethyl-4-piperidinyl)-
(CA INDEX NAME)



RN 1042659-84-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-
[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-ethyl-4-piperidinyl)-
, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042659-85-7 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-
[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-ethyl-4-piperidinyl)-
, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042659-86-8 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-
3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-ethyl-4-
piperidinyl)- (CA INDEX NAME)



RN 1042659-87-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-ethyl-4-piperidinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042659-88-0 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-ethyl-4-piperidinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042659-89-1 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-propyl-4-piperidinyl)- (CA INDEX NAME)



RN 1042659-90-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-propyl-4-piperidinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042659-91-5 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-propyl-4-piperidinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042659-92-6 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-propyl-4-piperidinyl)- (CA INDEX NAME)



RN 1042659-93-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-propyl-4-piperidinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042659-94-8 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-propyl-4-piperidinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042659-95-9 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-propyl-4-piperidinyl)- (CA INDEX NAME)



RN 1042659-96-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-propyl-4-piperidinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042659-97-1 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-propyl-4-piperidinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042659-99-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(1-propyl-4-piperidinyl)- (CA INDEX NAME)




RN 1042660-00-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-

oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(1-propyl-4-piperidinyl)-, (+)-
(CA INDEX NAME)


Rotation (+).



RN 1042660-01-4 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(1-propyl-4-piperidinyl)-, (-)-
(CA INDEX NAME)

Rotation (-).



RN 1042660-02-5 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-propyl-4-piperidinyl)- (CA INDEX NAME)



RN 1042660-03-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-
[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-propyl-4-
piperidinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-04-7 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-
[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-propyl-4-
piperidinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-05-8 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-
3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-propyl-4-
piperidinyl)- (CA INDEX NAME)



RN 1042660-06-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-propyl-4-piperidinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-07-0 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-propyl-4-piperidinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-08-1 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-[1-(1-methylethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 1042660-09-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-[1-(1-methylethyl)-4-piperidinyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-10-5 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-[1-(1-methylethyl)-4-piperidinyl]-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-11-6 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-[1-(1-methylethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 1042660-12-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-[1-(1-methylethyl)-4-piperidinyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-13-8 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-[1-(1-methylethyl)-4-piperidinyl]-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-14-9 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-[1-(1-methylethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 1042660-15-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-[1-(1-methylethyl)-4-piperidinyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-16-1 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-[1-(1-methylethyl)-4-piperidinyl]-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-17-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-[1-(1-methylethyl)-4-piperidinyl]- (CA INDEX NAME)




RN 1042660-18-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-

oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-[1-(1-methylethyl)-4-piperidinyl]-
, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-19-4 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-[1-(1-methylethyl)-4-piperidinyl]-
, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-20-7 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-[1-(1-methylethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 1042660-22-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-[1-(1-methylethyl)-4-piperidinyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-23-0 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-[1-(1-methylethyl)-4-piperidinyl]-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-24-1 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-[1-(1-methylethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 1042660-25-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-[1-(1-methylethyl)-4-piperidinyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-26-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-[1-(1-methylethyl)-4-piperidinyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1042660-27-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-piperidinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-28-5 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-piperidinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-29-6 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-piperidinyl)- (CA INDEX NAME)



RN 1042660-30-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-piperidinyl)-, (+)-
(CA INDEX NAME)


Rotation (+).



RN 1042660-31-0 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-piperidinyl)-, (-)-
(CA INDEX NAME)

Rotation (-).



RN 1042660-32-1 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-piperidinyl)-
(CA INDEX NAME)



RN 1042660-33-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-piperidinyl)-,
(+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-34-3 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-piperidinyl)-,
(-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-35-4 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(4-piperidinyl)- (CA INDEX NAME)



RN 1042660-36-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(4-piperidinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-37-6 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(4-piperidinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-38-7 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-piperidinyl)- (CA INDEX NAME)



RN 1042660-39-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-piperidinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-40-1 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-piperidinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-41-2 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-piperidinyl)- (CA INDEX NAME)



RN 1042660-42-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-piperidinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-43-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-piperidinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1042660-44-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-45-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1042660-46-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-47-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1042660-48-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, (+)-(CA INDEX NAME)


Rotation (+).



RN 1042660-49-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, (-)-(CA INDEX NAME)

Rotation (-).




RN 1042660-50-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-

[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-51-4 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-52-5 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 1042660-53-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-54-7 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-55-8 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)- (CA INDEX NAME)



RN 1042660-56-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-57-0 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-58-1 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)- (CA INDEX NAME)



RN 1042660-59-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-60-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1042660-61-6 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)-, (+)-(CA INDEX NAME)

Rotation (+).



RN 1042660-62-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)- (CA INDEX NAME)




RN 1042660-63-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-

[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)-
, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-64-9 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)-
, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-65-0 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)- (CA INDEX NAME)



RN 1042660-66-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-67-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1042660-68-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-69-4 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-70-7 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)- (CA INDEX NAME)



RN 1042660-71-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-72-9 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-73-0 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)- (CA INDEX NAME)



RN 1042660-74-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-75-2 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-76-3 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)- (CA INDEX NAME)



RN 1042660-77-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-78-5 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-79-6 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)- (CA INDEX NAME)



RN 1042660-80-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-81-0 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-82-1 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)- (CA INDEX NAME)



RN 1042660-83-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-84-3 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-85-4 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 1042660-86-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-87-6 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-88-7 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 1042660-89-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-90-1 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-91-2 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 1042660-92-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-93-4 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-94-5 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]-
(CA INDEX NAME)



RN 1042660-95-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]-
, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-96-7 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]-
, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042660-97-8 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 1042660-98-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042660-99-0 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042661-00-6 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 1042661-01-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042661-02-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 1042661-03-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-piperazinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042661-04-0 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-piperazinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042661-05-1 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-piperazinyl)- (CA INDEX NAME)



RN 1042661-06-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-piperazinyl)-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1042661-07-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-


[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-piperazinyl)-, (-)-
(CA INDEX NAME)

Rotation (-).



RN 1042661-08-4 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-piperazinyl)-
(CA INDEX NAME)



RN 1042661-09-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-piperazinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042661-10-8 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-piperazinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042661-11-9 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(1-piperazinyl)- (CA INDEX NAME)



RN 1042661-12-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(1-piperazinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042661-13-1 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(1-piperazinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042661-14-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-piperazinyl)- (CA INDEX NAME)




RN 1042661-15-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-piperazinyl)-, (+)-

(CA INDEX NAME)


Rotation (+).



RN 1042661-16-4 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-piperazinyl)-, (-)-
(CA INDEX NAME)

Rotation (-).



RN 1042661-17-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-piperazinyl)- (CA INDEX NAME)



CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-piperazinyl)-, (+)- (CA INDEX NAME)


CCOC(=O)C1=CC=C(C=C1)S(=O)(=O)N2C(=O)C3=C(C=C(C=C3)N)C(=O)N(C2C4=CC=C(C=C4)C#N)C(=O)N5CCCN(C5)CC6=CC=CC=C6

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-piperazinyl)-, (-)- (CA INDEX NAME)

CCOC(=O)N1C(=O)N2C(=O)N(C(=O)N3CCCN3CCN4CCCN4)C5=CC=CC=C5C2=C1C6=CC=CC=C6C=C7C=CC(=C7)N


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
dihydro-2-oxo-1H-indol-3-yl]-1'-methyl-, (+)- (CA INDEX NAME)

Rotation (+).



RN 1042661-22-2 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-methyl- (CA INDEX NAME)



RN 1042661-23-3 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-methyl-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1042661-24-4 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-methyl-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1042661-25-5 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-1'-methyl- (CA INDEX NAME)



RN 1042661-26-6 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-1'-methyl-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042661-27-7 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
dihydro-2-oxo-1H-indol-3-yl]-1'-methyl-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042661-28-8 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-
1H-indol-3-yl]-1'-methyl- (CA INDEX NAME)




RN 1042661-29-9 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,

N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-1'-methyl-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042661-30-2 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-1'-methyl-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1042661-31-3 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-methyl- (CA INDEX NAME)




RN 1042661-32-4 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-methyl-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1042661-33-5 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-methyl-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1042661-34-6 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-1'-methyl- (CA INDEX NAME)



RN 1042661-35-7 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-
2,3-dihydro-2-oxo-1H-indol-3-yl]-1'-methyl-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042661-36-8 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-
2,3-dihydro-2-oxo-1H-indol-3-yl]-1'-methyl-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1042661-37-9 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
 dihydro-2-oxo-1H-indol-3-yl]-1'-ethyl-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1042661-38-0 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-
 methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-ethyl- (CA INDEX NAME)



RN 1042661-39-1 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-
 methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-ethyl-, (+)- (CA INDEX
 NAME)


Rotation (+).



RN 1042661-40-4 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-
methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-ethyl-, (-)- (CA INDEX
NAME)

Rotation (-).




RN 1042661-41-5 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
dihydro-2-oxo-1H-indol-3-yl]-1'-ethyl- (CA INDEX NAME)




RN 1042661-42-6 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
 dihydro-2-oxo-1H-indol-3-yl]-1'-ethyl-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1042661-43-7 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
 dihydro-2-oxo-1H-indol-3-yl]-1'-ethyl-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1042661-44-8 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-
 1H-indol-3-yl]-1'-ethyl- (CA INDEX NAME)



RN 1042661-45-9 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-
1H-indol-3-yl]-1'-ethyl-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042661-46-0 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-
1H-indol-3-yl]-1'-ethyl-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042661-47-1 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-
methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-ethyl- (CA INDEX NAME)



RN 1042661-48-2 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-
methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-ethyl-, (+)- (CA INDEX
NAME)


Rotation (+).




RN 1042661-49-3 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-
methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-ethyl-, (-)- (CA INDEX
NAME)

Rotation (-).




RN 1042661-50-6 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-
 2,3-dihydro-2-oxo-1H-indol-3-yl]-1'-ethyl- (CA INDEX NAME)




RN 1042661-51-7 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-
 2,3-dihydro-2-oxo-1H-indol-3-yl]-1'-ethyl-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1042661-52-8 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-
 2,3-dihydro-2-oxo-1H-indol-3-yl]-1'-ethyl-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042661-53-9 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
dihydro-2-oxo-1H-indol-3-yl]-1'-propyl- (CA INDEX NAME)



RN 1042661-54-0 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
dihydro-2-oxo-1H-indol-3-yl]-1'-propyl-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1042661-55-1 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
 dihydro-2-oxo-1H-indol-3-yl]-1'-propyl-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1042661-56-2 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-
 methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-propyl- (CA INDEX NAME)



RN 1042661-57-3 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-
 methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-propyl-, (+)- (CA INDEX
 NAME)


Rotation (+).



RN 1042661-58-4 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-
methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-propyl-, (-)- (CA INDEX
NAME)

Rotation (-).



RN 1042661-59-5 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
dihydro-2-oxo-1H-indol-3-yl]-1'-propyl- (CA INDEX NAME)



RN 1042661-60-8 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
dihydro-2-oxo-1H-indol-3-yl]-1'-propyl-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042661-61-9 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
dihydro-2-oxo-1H-indol-3-yl]-1'-propyl-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042661-62-0 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-
1H-indol-3-yl]-1'-propyl- (CA INDEX NAME)



RN 1042661-63-1 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-
1H-indol-3-yl]-1'-propyl-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042661-64-2 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-
1H-indol-3-yl]-1'-propyl-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042661-65-3 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-
methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-propyl- (CA INDEX NAME)



RN 1042661-66-4 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-propyl-, (+)- (CA INDEX NAME)


Rotation (+).




RN 1042661-67-5 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-propyl-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1042661-68-6 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-
 2,3-dihydro-2-oxo-1H-indol-3-yl]-1'-propyl- (CA INDEX NAME)




RN 1042661-69-7 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-
 2,3-dihydro-2-oxo-1H-indol-3-yl]-1'-propyl-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1042661-70-0 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-
 2,3-dihydro-2-oxo-1H-indol-3-yl]-1'-propyl-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042661-71-1 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
dihydro-2-oxo-1H-indol-3-yl]-1'-(1-methylethyl)- (CA INDEX NAME)



RN 1042661-72-2 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
dihydro-2-oxo-1H-indol-3-yl]-1'-(1-methylethyl)-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1042661-73-3 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
 dihydro-2-oxo-1H-indol-3-yl]-1'-(1-methylethyl)-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1042661-74-4 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-
 methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-(1-methylethyl)- (CA
 INDEX NAME)



RN 1042661-75-5 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-
 methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-(1-methylethyl)-, (+)-
 (CA INDEX NAME)


Rotation (+).



RN 1042661-76-6 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-(1-methylethyl)-, (-)-
(CA INDEX NAME)

Rotation (-).




RN 1042661-77-7 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-1'-(1-methylethyl)- (CA INDEX NAME)




RN 1042661-78-8 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
 dihydro-2-oxo-1H-indol-3-yl]-1'-(1-methylethyl)-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1042661-79-9 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
 dihydro-2-oxo-1H-indol-3-yl]-1'-(1-methylethyl)-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1042661-80-2 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-
 1H-indol-3-yl]-1'-(1-methylethyl)- (CA INDEX NAME)



RN 1042661-81-3 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-
1H-indol-3-yl]-1'-(1-methylethyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042661-82-4 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-
1H-indol-3-yl]-1'-(1-methylethyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042661-83-5 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-
methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-(1-methylethyl)- (CA
INDEX NAME)



RN 1042661-84-6 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-(1-methylethyl)-, (+)-
(CA INDEX NAME)


Rotation (+).




RN 1042661-85-7 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-1'-(1-methylethyl)-, (-)-
(CA INDEX NAME)

Rotation (-).




RN 1042661-86-8 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-
 2,3-dihydro-2-oxo-1H-indol-3-yl]-1'-(1-methylethyl)- (CA INDEX NAME)




RN 1042661-87-9 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-
 2,3-dihydro-2-oxo-1H-indol-3-yl]-1'-(1-methylethyl)-, (+)- (CA INDEX
 NAME)

Rotation (+).



RN 1042661-88-0 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-
 2,3-dihydro-2-oxo-1H-indol-3-yl]-1'-(1-methylethyl)-, (-)- (CA INDEX
 NAME)


Rotation (-).



RN 1042661-90-4 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
dihydro-2-oxo-1H-indol-3-yl]-, (+)- (CA INDEX NAME)


Rotation (+).




RN 1042661-91-5 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
dihydro-2-oxo-1H-indol-3-yl]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 1042661-92-6 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-
 methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]- (CA INDEX NAME)




RN 1042661-93-7 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-
 methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1042661-94-8 CAPLUS
 CN [4,4'-Bipiperidine]-1-carboxamide,
 N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(2-
 methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042661-95-9 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
dihydro-2-oxo-1H-indol-3-yl]- (CA INDEX NAME)



RN 1042661-96-0 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-
dihydro-2-oxo-1H-indol-3-yl]-, (+)- (CA INDEX NAME)

Rotation (+).




RN 1042661-97-1 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,

N-[5-cyano-1-[(2-ethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-, (-)- (CA INDEX NAME)

Rotation (-).




IT 1042661-98-2P 1042661-99-3P 1042662-00-9P
1042662-01-0P 1042662-02-1P 1042662-03-2P
1042662-04-3P 1042662-05-4P 1042662-06-5P

RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prophetic drug candidate; novel substituted oxindole derivs. as vasopressin receptor ligands useful in prophylaxis and treatment of vasopressin-dependent diseases)

RN 1042661-98-2 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]- (CA INDEX NAME)



RN 1042661-99-3 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042662-00-9 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-
1H-indol-3-yl]-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042662-01-0 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-
methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]- (CA INDEX NAME)



RN 1042662-02-1 CAPLUS

CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-
methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 1042662-03-2 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-1-[(4-
methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1042662-04-3 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-
2,3-dihydro-2-oxo-1H-indol-3-yl]- (CA INDEX NAME)



RN 1042662-05-4 CAPLUS


CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-
2,3-dihydro-2-oxo-1H-indol-3-yl]-, (+)- (CA INDEX NAME)

Rotation (+).



RN 1042662-06-5 CAPLUS
CN [4,4'-Bipiperidine]-1-carboxamide,
N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-
2,3-dihydro-2-oxo-1H-indol-3-yl]-, (-)- (CA INDEX NAME)

Rotation (-).



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:824752 CAPLUS Full-text
DOCUMENT NUMBER: 149:153118
TITLE: Preparation of substituted oxindole derivative as
vasopressin receptor modulators
INVENTOR(S): Netz, Astrid; Oost, Thorsten; Geneste, Herve; Braje,
Wilfried Martin; Wernet, Wolfgang; Unger, Liliane;
Hornberger, Wilfried; Lubisch, Wilfried
PATENT ASSIGNEE(S): Abbott G.m.b.H. & Co. K.-G., Germany
SOURCE: PCT Int. Appl., 37pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent


LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008080972	A1	20080710	WO 2007-EP64621	20071228
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:

DE 2006-102006062506A 20061230

GI



AB The present invention relates to novel oxindole derivs. of the formula I to medicaments comprising them and to their use for the prophylaxis and/or treatment of diseases vasopressin dependent. Thus, I was provided in a multi-step synthesis starting from the reaction of 5-iodoisatin with 2-ethoxy-3-iodopyridine. I was tested in binding assay of Vasopressin receptor V1a, V1b and V2, and oxytocin receptor, the other biol. assays were described as well.


IT 1037238-36-0P, N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-ethylpiperazin-1-yl)piperidine-1-carboxamide

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(preparation of substituted oxindole derivative as vasopressin receptor modulators)

RN 1037238-36-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)- (CA INDEX NAME)



IT 1037238-68-8P 1037238-70-2P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted oxindole derivative as vasopressin receptor modulators)

RN 1037238-68-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)-, (+)- (CA INDEX NAME)


Rotation (+).




RN 1037238-70-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)-, (-)- (CA INDEX NAME)


Rotation (-).



IT 1037238-19-9P, 3-Amino-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxoindoline-5-carbonitrile 1037238-20-2P, Phenyl [5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]carbamate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of substituted oxindole derivative as vasopressin receptor modulators)
 RN 1037238-19-9 CAPLUS
 CN 1H-Indole-5-carbonitrile, 3-amino-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo- (CA INDEX NAME)



RN 1037238-20-2 CAPLUS
 CN Carbamic acid, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-3-pyridinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-, phenyl ester (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:619930 CAPLUS Full-text
DOCUMENT NUMBER: 147:52806
TITLE: Preparation of

1,3-dihydro-1-(phenylsulfonyl)-2H-indol-2-ones for the
treatment of vasopressin dependent diseases

INVENTOR(S): Oost, Thorsten; Lubisch, Wilfried; Wernet, Wolfgang;
Hornberger, Wilfried; Unger, Liliane; Geneste, Herve;
Netz, Astrid

PATENT ASSIGNEE(S): Abbott G.m.b.H. & Co. K.-G., Germany

SOURCE: PCT Int. Appl., 135pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007063123	A1	20070607	WO 2006-EP69180	20061201
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1957480	A1	20080820	EP 2006-819882	20061201
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
PRIORITY APPLN. INFO.:			DE 2005-102005059484A	20051202
			US 2005-742065P	P 20051202
			WO 2006-EP69180	W 20061201

OTHER SOURCE(S): MARPAT 147:52806

GI



AB Title compds. I [A = substituted aromatic, heteroarom., etc.; B = substituted aromatic, heteroarom., etc.; R1 = H, halo, CN, etc.; R2 = H, alkyl, O-alkyl, etc.;] and their pharmaceutically acceptable salts were prepared For example, claimed oxoindole II was prepared from 3-bromo-4-methoxybenzaldehyde in 5 steps. In vasopressin receptor V1b affinity assays, 235 examples of compds. I exhibited k_i values ranging from <10-1000 nM.


IT 940277-57-6P 940277-60-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of phenylsulfonylindol-2-ones for the treatment of vasopressin dependent diseases)

RN 940277-57-6 CAPLUS


CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[2-methoxy-5-[(4-methyl-1-piperazinyl)methyl]-3-pyridinyl]-1-[(4-methoxyphenyl)sulfonyl]-3-[(2S)-2-(2-oxazolyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



RN 940277-60-1 CAPLUS

CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[2-methoxy-5-[(methylamino)methyl]-3-pyridinyl]-1-[(4-methoxyphenyl)sulfonyl]-3-[(2S)-2-(2-oxazolyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:765145 CAPLUS Full-text
 DOCUMENT NUMBER: 145:210877
 TITLE: Preparation of 1,3-dihydro-2H-indol-2-one compounds and pyrrolidin-2-one compound fused with aromatic heterocycle as antagonists of arginine-vasopressin V1b receptor
 INVENTOR(S): Sekiguchi, Yoshinori; Kuwada, Takeshi; Hayashi, Masato; Nozawa, Dai; Amada, Yuri; Shibata, Tsuyoshi; Yamamoto, Shuji; Ohta, Hiroshi; Okubo, Taketoshi; Koami, Takeshi
 PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 674pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006080574	A1	20060803	WO 2006-JP301913	20060130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,				

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

US 20080318923 A1 20081225 US 2007-883236 20070726
PRIORITY APPLN. INFO.: JP 2005-21010 A 20050128
WO 2006-JP301913 W 20060130

OTHER SOURCE(S): MARPAT 145:210877
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The title compds. [I; ring A = each (un)substituted C6-14 aryl or aromatic heterocyclyl; P = a single bond, C1-5 alkylene; Q = each (un)substituted C6-14 aryl or aromatic heterocyclyl, Q1; RD and RE at 2 and 3 or 3 and 4 positions together form (un)substituted C1-3 alkylendioxy, (CH2)m-O, N-(un)substituted (CH2)m-NH or NH-(CH2)m, (CH2)m-S, O-(CH2)m-S, or S-(CH2)m-S (m = 2-4); R5 = Q2, Q3, etc.; R6 = H, halo, (un)substituted HO; R7 = H, halo, (un)substituted SH; or R6 and R7 together represent oxo; R9 = each (un)substituted OH, SH or NH2; R33 = H, (un)substituted C1-5 alkyl, C3-8 cycloalkyl, C1-5 alkoxy, C1-5 alkyl, C1-5 alkoxy, C1-5 alkylthio, etc.] or pharmacol. acceptable salts thereof are prepared. These compds. are highly selectively antagonistic to arginine-vasopressin V1b receptor over arginine-vasopressin V1a receptor and arginine-vasopressin V2 receptor, have high metabolic stabilities and show favorable migration into the brain and high concns. in the plasma. They provide drugs which are efficacious against pathol. conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, they provide drugs which have a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. Thus, reductive amination of (4R)-1-((3R)-5-chloro-3-[2-methoxy-5-(2-oxoethyl)phenyl]-1-([4-methoxy-2-(trifluoromethoxy)phenyl]sulfonyl)-2-oxo-2,3-dihydro-1H-indol-3-yl)-4-hydroxy-N,N-dimethyl-L-prolinamide with piperidine using sodium triacetoxymethylborohydride in the presence of acetic acid in a mixture of THF and CHCl3 gave (+)-(4R)-1-[5-chloro-3-[5-[2-(dimethylamino)ethyl]-2-methoxyphenyl]-1-([4-methoxy-2-(trifluoromethoxy)phenyl]sulfonyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-L-prolinamide (II). II inhibited the binding of [3H](Arg8)vasopressin to human arginine vasopressin V1b, V1a, and V2 receptor with IC50 of 0.32, 102, and 5,050, nM, resp.

IT 905082-38-4P 905097-54-3P 905097-81-6P
905098-03-5P 905098-10-4P 905098-17-1P
905098-65-9P 905098-85-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of 1,3-dihydro-2H-indol-2-ones and pyrrolidin-2-ones fused
with aromatic heterocycle as selective antagonists of arginine vasopressin V1b
receptor)
RN 905082-38-4 CAPLUS
CN 2-Piperidinecarboxamide, 1-[5-chloro-2,3-dihydro-1-[[4-methoxy-2-
(trifluoromethoxy)phenyl]sulfonyl]-2-oxo-3-(2-pyridinyl)-1H-indol-3-yl]-
N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 905097-54-3 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxy-5-methyl-3-pyridinyl)-1-[[4-methoxy-2-(2,2,2-trifluoroethoxy)phenyl]sulfonyl]-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 905097-81-6 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[[2-(difluoromethoxy)-4-methoxyphenyl]sulfonyl]-2,3-dihydro-3-(2-methoxy-3-pyridinyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 905098-03-5 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxy-5-methyl-3-pyridinyl)-2-oxo-1-[(2,4,5-trimethoxyphenyl)sulfonyl]-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 905098-10-4 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxy-5-methyl-3-pyridinyl)-2-oxo-1-[(2,3,4-trimethoxyphenyl)sulfonyl]-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 905098-17-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxy-5-methyl-3-pyridinyl)-2-oxo-1-[(2,4,6-trimethoxyphenyl)sulfonyl]-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 905098-65-9 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[[3,4-dimethoxy-5-(trifluoromethoxy)phenyl]sulfonyl]-2,3-dihydro-3-(2-methoxy-3-pyridinyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A





RN 905098-85-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[[3,4-dimethoxy-2-(trifluoromethoxy)phenyl]sulfonyl]-2,3-dihydro-3-(2-methoxy-3-pyridinyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:284200 CAPLUS Full-text
 DOCUMENT NUMBER: 142:355286
 TITLE: Preparation of heteroaryl-substituted
 1,3-dihydroindol-2-one derivatives and medicaments
 containing them
 INVENTOR(S): Lubisch, Wilfried; Hornberger, Wilfried; Oost,
 Thorsten K.; Sauer, Daryl Richard; Unger, Liliane;
 Wernet, Wolfgang
 PATENT ASSIGNEE(S): Abbott GmbH & Co. Kg, Germany
 SOURCE: U.S. Pat. Appl. Publ., 24 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050070718	A1	20050331	US 2003-675300	20030930
CA 2537598	A1	20050407	CA 2004-2537598	20040930
WO 2005030755	A1	20050407	WO 2004-EP10940	20040930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1667993	A1	20060614	EP 2004-765719	20040930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007507456	T	20070329	JP 2006-530059	20040930
MX 2006PA03558	A	20060831	MX 2006-PA3558	20060330
US 20070021607	A1	20070125	US 2006-440569	20060525
US 20070185126	A1	20070809	US 2007-574211	20070122
PRIORITY APPLN. INFO.:			US 2003-675300	A 20030930
			WO 2004-EP10940	W 20040930
OTHER SOURCE(S):			CASREACT 142:355286; MARPAT 142:355286	
GI				



AB The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivs. of the formula (I) [A = each (un)substituted aromatic heteromonocyclic or aromatic or partially aromatic heterobicyclic ring, where the heterocycles are 5- or 6-membered rings and comprise up to 4 heteroatoms selected from the group consisting of N, O and S, and up to 2 oxo groups; R3, R4, R6, R7 = H, Cl, Br, iodo, F, cyano, CF3, OCF3, NO2, OH, C1-4 alkoxy, PhO, phenyl-C1-4 alkenyloxy, Ph, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, NH2, mono- or di(C1-4 alkyl)amino; or R3 and R4 are connected to give -CH:CH-CH:CH-, -(CH2)4- or -(CH2)3-; R5 = a radical (W)-(X)-(Y)-Z; where W = C1-4 alkylene, C2-4 alkenylene, C2-4 alkynylene, O, O-(C1-4 alkylene), S, S-(C1-4 alkylene), N-(un)substituted NH or NH-(C1-4 alkylene), a bond; X = CO, CO-O, SO2, each (un)substituted NH, NH-CO, NH-SO2, or CO-NH, a bond; Y = C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, a bond; Z = H, E, each (un)substituted OH, NH2, or SH; where E = (un)substituted, unsatd., saturated or partially unsatd. mono, bi- or tricyclic ring having a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms and/or 0 to 2 sulfur atoms;] and their tautomeric forms, enantiomeric and diastereomeric forms, and prodrugs thereof. These compds. can be used for the control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases, for example for the treatment of (1) depressions and/or bipolar disorders such as dysthymic disorders, subsyndromal depression, seasonal affected disorders, premenstrual dysphoric disorders and/or psychotic disorders, (2) anxiety and/or stress-related disorders such as, for example, general anxiety disorders, panic disorders, obsessive-compulsive disorders, posttraumatic disorders, acute stress disorders and/or social phobia, (3) memory disorders and/or Alzheimer's disease, (4) psychoses and/or psychotic disorders, or (5) Cushing's syndrome. Thus, (2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid dimethylamide hydrochloride (0.78 g, 4.0 mmol) was added to a solution of 3-(benzothiazol-2-yl)-3,5-dichloro-1,3-dihydroindol-2-one, in a mixture of dichloromethane 9, THF 2 and diisopropylethylamine 2 mL and the reaction mixture was stirred at room temperature for 48 h to give, after workup and silica gel chromatog., two diastereomers of (2S,4R)-1-[3-(Benzothiazol-2-yl)-5-chloro-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxypyrrolidine-2-carboxylic acid dimethylamide. NaH (12 mg 60% dispersion in mineral oil) was added to an ice-cold solution of the less polar diastereomer product from the above (115 mg, 0.25 mmol) in DMF (1.5 mL). The reaction mixture was stirred at 0° for 1 h and then treated with 2,4-dimethoxyphenylsulfonyl chloride (71 mg, 0.3 mmol), and stirred at room temperature for 1 h to give, after workup and silica gel chromatog., 93 mg (+)-(2S,4R)-1-[3-(benzothiazol-2-yl)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-

hydroxypyrrolidine-2-carboxylic acid dimethylamide (II) as a white solid. II
in vitro binding affinity to vasopressin V1b receptor with <50 nM.

IT 1056963-50-8 1056963-51-9 1056963-53-1
1056963-54-2 1056963-55-3 1056963-56-4
1056963-57-5 1056963-58-6 1056963-61-1
1056963-63-3 1056963-66-6 1056963-70-2
1056963-71-3


RL: PRPH (Prophetic)

(Preparation of heteroaryl-substituted 1,3-dihydroindol-2-one
derivatives and medicaments containing them)


RN 1056963-50-8 CAPLUS

CN 4-Piperidinecarboxamide, N-[5-chloro-2,3-dihydro-3-(2-methoxy-3-pyridinyl)-
2-oxo-1-(8-quinolinylsulfonyl)-1H-indol-3-yl]-1-(4-pyridinyl)- (CA INDEX
NAME)

PAGE 1-A




PAGE 2-A



RN 1056963-51-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(
(2,4-dimethoxy-5-pyrimidinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-
N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1056963-53-1 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxy-3-pyridinyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 1056963-54-2 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methyl-3-pyridinyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 1056963-55-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2-chloro-3-pyridinyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 1056963-56-4 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(4-methyl-3-pyridinyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-

dimethyl-, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056963-57-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-3-(2-pyrazinyl)-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)



Absolute stereochemistry.



RN 1056963-58-6 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(3,6-dimethoxy-4-pyridazinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1056963-61-1 CAPLUS
 CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-
 2,3-dihydro-2-oxo-3-(2-thiazolyl)-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-,
 (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056963-63-3 CAPLUS
 CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-
 2,3-dihydro-3-(1-methyl-1H-imidazol-2-yl)-2-oxo-1H-indol-3-yl]-4-hydroxy-
 N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056963-66-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(3-methyl-2-thienyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056963-70-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(3-methyl-2-furanyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056963-71-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(3-furanyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 848865-40-7P 848865-42-9P 848865-44-1P
848865-46-3P 848865-48-5P 848865-50-9P
848865-52-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroaryl(phenylsulfonyl)dihydroindolone derivs. for control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases)

RN 848865-40-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(3R)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2,4-dimethoxy-5-pyrimidinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 848865-42-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(3S)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2,4-dimethoxy-5-pyrimidinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848865-44-1 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[(3S)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxy-3-pyridinyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 848865-46-3 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[(3R)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxy-3-pyridinyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 848865-48-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(3-methoxy-2-pyridinyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 848865-50-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(4-methoxy-3-pyridinyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-

dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848865-52-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(3-methoxy-2-pyrazinyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



=> D HIS

(FILE 'HOME' ENTERED AT 10:02:37 ON 30 DEC 2008)

FILE 'REGISTRY' ENTERED AT 10:03:12 ON 30 DEC 2008

L1 STRUCTURE UPLOADED
L2 21 S SSS SAM L1
L3 412 S SSS FULL L1
 SAVE TEMP L3 WILF10574211/A
L4 STRUCTURE UPLOADED
L5 19 S L4 SAM SUB=L3
L6 362 S L4 FULL SUB=L3

 FILE 'CAPLUS' ENTERED AT 10:11:20 ON 30 DEC 2008
L7 8 S L6

=> S L7 AND (AY<2003 OR PY<2003 OR PRY<2003)
 4501501 AY<2003
 22977253 PY<2003
 3970197 PRY<2003
L8 0 L7 AND (AY<2003 OR PY<2003 OR PRY<2003)

=> LOGOFF Y		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	56.20	282.85
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-6.40	-6.40

STN INTERNATIONAL LOGOFF AT 10:19:13 ON 30 DEC 2008